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Introduction: Aim of this study is to determine whether quality of life (QoL) assessment in association
with instrumental evaluation can help to identify factors predictive of outcome both in surgically and
medically treated GERD patients.
Methods: Between January 2005 and June 2010, 301 patients affected with GERD were included in the
study. QoL was evaluated by means of GERD-HRQL and SF-36 questionnaires administered before
treatment, at 6 months, at 1 year follow-up and at the end of the study. The multivariate analysis was
used to detect if variables such as sex, age, heartburn, acid regurgitation, dysphagia, presence of
esophagitis, percentage of total time at pH < 4, symptom index score (SI), the SF-36 and HRQL scores
before treatment, at 6 months and 1 year could affect the QoL questionnaires scores at the end of the
study.
Results: One hundred forty-seven patients were included in the surgical group and 154 in the medical
group. No differences with regard to gender, age, mean SF-36 and HRQL scores before treatment were
documented. At the end of the study, quality of life was signiﬁcantly improved for SF-36 and HRQL
scores, either for surgical or medical group. The multivariate analysis showed no factors individually
affected the SF-36 and the HRQL scores, but symptom index score (SI) and QoL questionnaires scores at 6
months and 1 year follow-up.
Conclusions: The combined use of pHmetry with evaluation of SI and QoL questionnaires can predict the
outcome of GERD patients managed either by medical or surgical therapy.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.. Rossetti), limpao@libero.it
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Gastroesophageal reﬂux disease (GERD) develops when the
reﬂux of stomach contents causes troublesome symptoms and/or
complications [1]. The aims of treatment are symptoms resolution,
esophagitis healing, prevention of complications and relapse.
During the past two decades, quality of life (QoL) assessment has
become an important end point in the treatment of many chronic
diseases such as GERD. Although proton-pump inhibitors (PPI) are
effective in the treatment of esophagitis and symptoms’ control,
studies have demonstrated that up to 40% of patients continue to
experience abnormal acid reﬂux on 24-h pH testing [1] and up to
35% of them present a relapse of symptoms during a 3-year follow-.
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increasing doses of PPIs to control symptoms and some of them
also a surgical deﬁnitive treatment. To date, the role of laparoscopic
total fundoplication (LTF) is well established in chronic GERD and
efforts to develop QoL instruments that effectively demonstrate
patient satisfaction and perceived well-being after operation rep-
resents an active research ﬁeld. Short Form 36 (SF-36) [3] is a
validated, reliable, generic instrument utilized in the follow up of
GERD patients. However, the Gastroesophageal Reﬂux Disease-
Health-Related Quality of Life (GERD-HRQL) questionnaire devel-
oped by Velanovich et al. is a disease speciﬁc QoL instrument
proposed to be more responsive to the effects of treatment and
more sensitive to changes in symptoms [4e6]. Aim of this study is
to determine whether QoL measurement in association with
instrumental evaluation can help to identify factors predictive of
outcome both in surgically and medically treated patients.
2. Methods
A prospective electronic database of all patients treated for
GERD at the Digestive Surgical Unit of the Second University of
Naples were reviewed. The diagnostic workup for GERD for pa-
tients who had typical or atypical symptoms of GERD included
barium swallow, esophagogastroduodenoscopy, stationary esoph-
ageal manometry and esophageal 24-h pH monitoring. At this last
instrumental examination the symptom index score (SI) was eval-
uated. A positive SI (>50%) was deﬁned when more than 50% of
symptoms reported by the patients were associated with docu-
mented reﬂux episodes. Inclusion criteria were: the patient had to
be over 16 years of age, had to have a diagnosis of GERD based on
the presence of esophagitis at upper GI endoscopy or abnormal
esophageal exposure at 24-h ambulatory pH testing, patients suc-
cessfully treated with medical therapy who accepted the alterna-
tive of undergoing antireﬂux surgery, no continuous treatment
with any acid-suppressant drug for more than seven days in the
four weeks before study entry. The symptoms and their inﬂuence
on the QoL were evaluated by means of the GERD-HRQL ques-
tionnaire [4e6]. It consists of 10 questions that assess the severity
of heartburn in orthostatic and supine position, in post-prandial
and night time, the effects on dietary habits, dysphagia, odyno-
phagia, abdominal distension in the post-prandial period,
discomfort in drugs intake and how the patients deﬁne their gen-
eral statement. The ﬁnal score is obtained by adding the value
assigned to each question and it varies from 0 for asymptomatic
patients to 50 for patients with signiﬁcant limitations in QoL.
The QoL was also evaluated using the Italian version of SF-36
questionnaire [3] which investigates about perceived health sta-
tus and provides information on health and well being, through
eight functions: physical function, role limitations (physical, bodily
pain, vitality, general health perceptions, social functioning),
emotional and mental health. The Italian translation of the ques-
tionnaire was previously validated using objective psychometric
criteria. The score ranges from 0 to 100 with the maximum that
indicates the best perception of QoL. Both questionnaires were
administered to patients in presence of the same physician before
treatment, at 6 months, at 1 year follow up and at the end of the
study.
2.1. Medical treatment
Medical treatment involved any one of the four different PPIs:
rabeprazole 10 mg (Janssen Pharmaceuticals, New Jersey, USA),
pantoprazole 20 mg (Knoll Pharmaceuticals, New Jersey, USA),
lansoprazole 15 mg (Wyeth Pharmaceuticals, New Jersey, USA) and
omeprazole or esomeprazole 20 mg (Astra Zeneca, Sodertalje,Sweden). The daily dose of PPI was kept at or adjusted to a level that
abolished all reﬂux symptoms and expressed as multiples of the
above doses.
2.2. Surgical therapy
Patients addressed to surgery underwent LTFwith the technique
previously described [7e14]. Brieﬂy, the procedure began with the
section of the anterior peritoneal reﬂection of the gastroesophageal
junction. After identiﬁcation of the anterior vagal nerve, the gas-
trophrenic ligament was divided. The dissection was then
continued from right to left behind the esophagus until the crura
was exposed, and the angle of His was abolished, with particular
care taken to avoid injury to the posterior vagus. At this point a
posterior window was created large enough to accommodate
fashioning of the wrap. The esophagus was widely mobilized in its
mediastinal portion until the esophagus laid in the abdomen
without tension. The cruroplasty was accomplished by one simple
extracorporeal non absorbable knot. The 2-cm-long total fundo-
plicationwas fashioned with the anterior wall of the gastric fundus.
The short gastric vessels were always preserved. The two gastric
hemi-valves were sutured with two stitches that never incorpo-
rated the esophageal muscular layer. In all cases, to check the
calibration of the wrap, at the end of the procedure an intra-
operative manometry and an endoscopic control were performed.
2.3. Statistical analysis
Statistical analysis was performed on the patients who
completed the postoperative evaluation using SPSS for Windows
(version 17.0; SPSS, Inc., Chicago, IL). Results are expressed as the
mean ± SD unless otherwise indicated. Continuous variables were
compared by the unpaired and paired Student t test and dichotomic
variables were compared by the chi-squared test. Two general
linear models were constructed with postoperative SF36 and
GERD-HRQL questionnaires in the medical and surgical group as
dependent variables each including all the covariates that previ-
ously had been shown to be signiﬁcant at the a level of less than
0.05.
The multivariate analysis was used to detect if variables such as
sex, age, heartburn, acid regurgitation, dysphagia, presence of
esophagitis, percentage of total time at pH < 4, the symptom index
score, the SF36 score and HRQL score pre-treatment, at 6 months
and 1 year could affect the QoL questionnaires score at the end of
the study either in medical and surgical group.
3. Results
Three hundred and one out of 315 selected patients completed
the study. They were divided in two groups according to the type of
treatment: Surgical group, comprising 147 patients (67 males, 80
females, mean age 42.9 ± 14.2) who underwent LTF; medical group,
comprising 154 patients (61 males, 93 females, mean age
40.5 ± 15.2) who underwent treatment with PPI. Demographic and
preoperative data are summarized in Table 1. No statistically sig-
niﬁcant differences between the two groups with regard to gender,
age, incidence of typical symptoms (heartburn and acid regurgi-
tation), mean SF-36 and HRQL scores were documented. Post-
operatively, quality of life was signiﬁcantly improved either for SF-
36 (mean 74.3 ± 7.1; p < 0.0001) or HRQL scores (mean 10.6 ± 5.3;
p < 0.0001) in the surgical group. Similarly, better SF-36 (mean
72.1 ± 17.1; p < 0.0001) and HRQL (mean 11.5 ± 6.4; p < 0.0001)
scores were recorded in the medical group. Moreover, no differ-
ences were observed in both questionnaires scores SF-36 (p ¼ 0.14)
and HRQL (p ¼ 0.18) between the two groups at the evaluation at
Table 3
Multiple regression analysis of factors associated with HRQL at the end of the study
in the medical and surgical group.
Factors Medical group Surgical group
(P < 0.05) (P < 0.05)
Sex 0.278 0.3613
Age 0.865 0.8263
Heartburn 0.338 0.3938
Regurgitation 0.603 0.6136
Dysphagia 0.356 0.246
Esophagitis 0.07 0.09
pHmetryþ 0.0654 0.0724
SIþ 0.03 0.008
SI 0.288 0.323
SF36 pre-treatment 0.512 0.5143
HRQL at 6 months 0.003 0.0001
HRQL at 1 year 0.006 0.005
Table 1
Demographic and preoperative data.
Surgical group Medical group P
N of pts 147 154 NS
Sex (m/F) 67/80 61/93 NS
Age NS
Mean (stand dev.) 42.9 (14.2) 40.5 (15.2)
Range (minemax) 19e79 17e78
Heartburn (%) 84 88 NS
Acid regurgitation (%) 78 79 NS
pH-metry 8 (13.2) 7.3 (11.1) NS
(%t. tot ph < 4/24 h)
Mean (Stand. dev.)
HRQL 30.4 (9.1) 29.2 (8.8) NS
Mean (Stand. dev.)
SF-36 55.8 (16.9) 56.9 (20.3) NS
Mean (Stand. dev.)
Follow-up NS
Mean (stand dev) 29.2 (7.5) 28.3 (6.4)
range (minemax) 12e41 16e41
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individually affected the SF36 and the HRQL scores, but pHmetry
symptom index score (SI) and QoL questionnaires scores recorded
at 6 months and one year follow up (Tables 2 and 3). Patients with
an SI > 50% at the beginning of the study, either in medical and
surgical group, showed a signiﬁcantly better clinical outcome, in
terms of SF-36 and HRQL scores, compared with those with an
SI < 50%. Instead, neither typical nor atypical symptoms (heartburn,
regurgitation, dysphagia), presence of esophagitis or pathological
pHmetry alone inﬂuenced the SF-36 and HRQL scores at the end of
the study either in medical and surgical group (Tables 2 and 3).4. Discussion
Although laparoscopic surgery in the last twenty years ach-
ieved excellent results in the treatment of GERD, at present no
deﬁnitive conclusions about the choice between surgical or
medical therapy can be drawn. Different randomized prospective
trials have been conducted but the argument remains contro-
versial [2,15e20]. In a previous randomized study, Lundell and
coworkers [2] found antireﬂux surgery more effective than
omeprazole at a dose of 20 mg per day in controlling GERD
measured by treatment failure rates. However, after adjusting
omeprazole dose at 40 or 60 mg daily, the differences between the
two therapeutic strategies became not statistically signiﬁcant [2].
In contrast, Spechler et al. [18] did not observe any signiﬁcant
differences in SF-36 scores and satisfaction after surgical and
medical therapy at 10 years follow up. A larger recent study with aTable 2
Multiple regression analysis of factors associatedwith SF36 at the end of the study in
the medical and surgical group.
Factors Medical group Surgical group
(P < 0.05) (P < 0.05)
Sex 0.236 0.151
Age 0.654 0.174
Heartburn 0.456 0.845
Regurgitation 0.478 0.922
Dysphagia 0.663 0.753
Esophagitis 0.223 0.123
pHmetryþ 0.666 0.573
SIþ 0.02 0.003
SI 0.123 0.274
SF36 pre-treatment 0.07 0.409
SF36 at 6 months 0.03 0.01
SF36 at 1 year 0.0001 0.00015 year follow up [19] documented no differences betweenmedical
and surgical groups in terms of postoperative GERD remission
(85% vs 92%, respectively) (p ¼ NS). However, an universally
accepted deﬁnition and evaluation of treatment success/failure of
GERD is still controversial as stated in a recent study [21]. Authors
observed that the most consistent parameter to better deﬁne
treatment success was patient’s satisfaction, with a reported
mean satisfaction rate as high as 88.9%. In the present study, the
employment of both general and health related QoL question-
naires was based on previous evidence supporting these outcome
measures as able to well deﬁne long term outcome of GERD pa-
tients. Speciﬁcally, we found medical and surgical treatments
were comparable in terms of postoperative QoL outcomes.
Instead, instrumental evaluation such as 24-h esophageal pH
monitoring may be not helpful, since no correlation between
symptoms response and esophageal acid exposure at post-
operative evaluation had been detected [22e24]. In fact, Jenkin-
son et al. [24] have found that among 30 patients becoming
asymptomatic after medical treatment, eighteen still presented a
pathologic GERD at pHmetric study. At the same time, among 19
patients who reported persistent symptoms after surgery, only
two presented a real pathologic gastroesophageal acid reﬂux at
pHmetry. These contradictory results have been conﬁrmed also in
more recent studies [25,26]. Several Authors showed that QoL
scores evaluation is strictly related to clinical outcome of GERD
patients [27e30]. Persistent reﬂux symptoms on PPI therapy seem
associated with worse physical and mental HRQL, whereas pa-
tients responders to PPI therapy report a signiﬁcant improvement
of HRQL. Another question might be on what objective and sub-
jective variables are able to predict patients response to either
medical or surgical treatment. The present study showed that
neither the presence of typical or atypical symptoms, nor the
esophagitis as well as a pathological pHmetry alone in the pre-
operative evaluation, inﬂuenced clinical outcome of either med-
ical and surgical groups. Instead, preoperative positive SI and a
good short-term postoperative QoL were independent factors
associated with a better long-term QoL. Our ﬁndings are in line
with those previously reported by Shimatani et al. [31], who found
that the satisfactory heartburn-relief rate after 4 weeks of medical
therapy with a standard dose PPI was signiﬁcantly higher in pa-
tients with a positive SI, compared with those with a negative SI.
However, we extended their conclusions even to surgically treated
patients, suggesting that preoperative pH monitoring and conﬁr-
mation of a positive SI can help to predict the efﬁcacy either of
medical or surgical GERD therapy. On the contrary, Zerbib et al.
[32] reported that no reﬂux pattern detected at 24 h pH-
impedance monitoring was predictive of response to medical
G. Rossetti et al. / International Journal of Surgery 12 (2014) S112eS116 S115treatment. Other studies evaluating the impact of surgery on
GERD population reported conﬂicting results regarding the role of
24-h pHmetry in predicting postoperative outcome [33e36]. At
last, the most interesting ﬁnding of the present study is the pre-
dictive value a positive SI may have on long-term QoL after
medical or surgical treatment.
In conclusion, we support the combined use of pHmetry with
evaluation of SI and QoL questionnaires to assess and predict long-
term outcome in GERD patients managed either by medical or
surgical therapy.
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